Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (365)	12/2/2002 9:11:59 AM
From: scaram(o)uche	Read Replies (1) of 598

Dow Jones Business News Tularik Asks For Trial For Compound For Metabolic Disease Monday December 2, 9:04 am ET WASHINGTON -(Dow Jones)- Tularik Inc. (NasdaqNM:TLRK - News) said it submitted all documents necessary to request initiation of a Phase 1 clinical trial to evaluate one of its advanced lead compounds for metabolic disease, according to a Form 8-K filed Monday with the Securities and Exchange Commission. Tularik, South San Francisco, Calif., said it submitted the documents to an ethics committee in the U.K. The clinical trial would evaluate the safety and tolerability of the lead compound, according to the filing. Tularik develops oral drugs that use gene regulation to treat onditions such as diabetes, cancers, cytomegalovirus, obesity and inflammatory diseases. Carrie DeLeon,Dow Jones Newswires; 202-628-7663

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next